Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Better Buy: Moderna vs. Biocryst Pharmaceuticals

TheMotleyFool

0 0

Better Buy: Moderna vs. Biocryst PharmaceuticalsPhoto, wide shot, wide-angle lens, Mental health care service, Midday, harsh overhead sunlight, directional sunlightt, photo by Art Wolfe: https://img.midjourneyapi.xyz/temp/7ce3b930-5e2a-4215-b686-0ad0eb0b922a.png

Most stocks have performed dismally so far in 2020 due to the COVID-19 outbreak. But biotech stocks, in general, have fared pretty well. Some have even delivered exceptional returns in recent months.

Moderna (NASDAQ: MRNA) is definitely in that category, with its shares skyrocketing 160% higher. Biocryst Pharmaceuticals (NASDAQ: BCRX) is an example of a biotech stock that hasn't been a huge winner but still outperformed major market indexes. Its shares are down slightly year to date -- much better than the double-digit percentage decline for the S&P 500 index.

Which of these two biotech stocks is the better pick for investors going forward? Here's how Moderna and Biocryst compare.

Source Fool.com

Like: 0

BCRX

Teilen